Background Biomarkers to identify lung cancer (LC) patients with high risk of venous
thromboembolism (VTE) are needed. Objectives To evaluate the usefulness of plasma …

Purpose Circulating tissue factor (TF) has been studied as a biomarker for predicting initial,
but not recurrent, venous thromboembolism (VTE) in cancer, a setting in which predictors …

Several other biomarkers are currently under investigation. The most prominent area of
focus is tissue factor, a physiologic initiator of coagulation. In addition to its procoagulant …

Introduction Tissue factor (TF) is the physiological trigger of blood coagulation, but it could
also have an important role in cancer by regulating VEGF expression and angiogenesis …

Background: VTE is a common complication in lung cancer patients and is associated with
an increased mortality. The tight and reciprocal interaction between cancer and hemostasis …

Pancreatic cancer is the fourth leading cause of cancer death in the US [1]. It is frequently
complicated by venous thromboembolism (VTE), with published incidence rates varying …

TO THE EDITOR: We congratulate Khorana et al 1 for their useful description of tissue factor
(TF) as a potential biomarker for recurrent venous thromboembolism (VTE) in patients with …

Activation of blood coagulation contributes to cancer progression. Tissue factor pathway
inhibitor‐1 (TFPI‐1) is the main inhibitor of extrinsic coagulation pathway. The aim of this …

Method Total TFPI antigen levels at study inclusion (Imunbind total TFPI ELISA kit, American
Diagnostica Inc., USA) were measured in patients included in the Vienna Cancer and …

Cancer patients exhibit a high rate of thromboembolism (VTE). In this study, we analyzed
levels of microparticle (MP) tissue factor (TF) activity in cancer patients with or without VTE …